LYRA News and Press, Lyra Therapeutics Inc. From 05/24/21

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that Maria Pal...

Lyra Therapeutics, Inc. (LYRA) Q1 2021 Earnings Conference Call May 11, 2021 04:30 PM ET Company Participants Stephen Jasper - Principal, Gilmartin Group Maria Palasis - President and Chief Executive Officer Rob Kern - Chief Medical Officer Don Elsey - Chief Financial Officer Conference Call ...

Lyra Therapeutics (LYRA): Q1 GAAP EPS of -$0.60 misses by $0.12.Cash and cash equivalents of $66.1M.Press Release For further details see: Lyra Therapeutics EPS misses by $0.12

- Presented positive full data from LANTERN Phase 2 study of LYR-210 at COSM – - Appointed Robert Kern, MD, as Chief Medical Officer - - Conference call and webcast today at 4:30 p.m. ET - Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics compa...

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that Maria Pal...

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced the company wi...

Gainers: Sypris Solutions (SYPR) +75%.Ocugen (OCGN) +41%.Brooklyn ImmunoTherapeutics (BTX) +34%.MicroVision (MVIS) +32%.BioVie (BIVI) +29%.FreightCar America (RAIL) +27%.Uxin (UXIN) +26%.Birks Group (BGI) +24%.Meridian Bancorp (EBSB) +21%.22nd Century (XXII) +20%.Losers: I...

New data presented includes: - First product candidate found to be effective in non-polyp patients in addition to polyp patients in a clinical trial, based on 100% of patients in both groups achieving SNOT-22 MCID at week 24 with LYR-210 (7500µg group) - - LYR-210...

- LYR-210 is Lyra’s lead product candidate for chronic rhinosinusitis - Lyra Therapeutics, Inc . (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localize...

Lyra Therapeutics, Inc. (LYRA) Q4 2020 Earnings Conference Call March 09, 2021 04:30 PM ET Company Participants Laurence Watts - Managing Director, Gilmartin Group Maria Palasis - President & Chief Executive Officer Rob Kern - Chief Medical Officer Don Elsey - Chief Financial Officer Cori...